(Q37771953)

22 August 2017

1 reference

title

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

Rudolph M Navari

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1073-1084

1 reference

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

22 August 2017

cites work

1 reference

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

21 January 2018

1 reference

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.

21 January 2018

1 reference

Emerging drugs for chemotherapy-induced emesis

21 January 2018

1 reference

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments

21 January 2018

1 reference

Delayed emesis: moderately emetogenic chemotherapy

21 January 2018

1 reference

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

21 January 2018

1 reference

Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists

21 January 2018

1 reference

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

21 January 2018

1 reference

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

21 January 2018

1 reference

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

21 January 2018

1 reference

Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).

21 January 2018

1 reference

The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

21 January 2018

1 reference

Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor

21 January 2018

1 reference

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function

21 January 2018

1 reference

Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects

21 January 2018

1 reference

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

21 January 2018

1 reference

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study

21 January 2018

1 reference

Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

21 January 2018

1 reference

Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience

21 January 2018

1 reference

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

21 January 2018

1 reference

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

21 January 2018

1 reference

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.74

1 reference

22 August 2017

1 reference